Thermo Fisher Scientific will showcase its latest flexible solutions to help boost efficiency and scale in biopharmaceutical manufacturing during CPHI Frankfurt 2025.
Leaders from across the organisation will participate in a series of panel discussions highlighting industry trends, sustainability strategies and how collaboration can accelerate delivery of life-changing medicines to market.
“Our goal is to streamline the drug discovery, development and manufacturing process to help customers provide the highest quality treatments to patients in need, both safely and efficiently.”
“Throughout the past year, we continued to leverage the breadth and depth of our offerings and expertise to do so — not only as the preferred partner between discovery and delivery, but also by providing innovative solutions that allow our pharma and biotech partners to mitigate risks as they tackle global health challenges,” said Michael Shafer, Executive Vice President and President, biopharma services, Thermo Fisher Scientific.
Since being introduced back in October of 2024, Thermo Fisher's Accelerator Drug Development has demonstrated progress across manufacturing, clinical research and clinical supply.
It has been backed by research such as findings from the Tufts Center for the Study of Drug Development (CSDD), which released results earlier this year confirming the benefits of such a solution.
To date, the company has leveraged the solution to partner across 700 programmes, spanning 14 therapeutic areas, led by oncology and neurology.
Now, under the umbrella of Accelerator Drug Development, Thermo Fisher is launching OSDPredict, a digital toolbox combining multiple AI and machine learning models to predict formulation behaviour and address key challenges in small-molecule development.
By delivering data-driven insights, OSDPredict aims to help biotech innovators save valuable active pharmaceutical ingredients, shorten timelines, mitigate risks and better understand molecule behaviour.
Additionally, the company added afucosylated cell line technology to its biologic cell line development portfolio, part of Thermo Fisher's comprehensive suite of large molecule biologics service offerings.
Thermo Fisher has also announced a strategic collaboration focused on the use of artificial intelligence (AI) with OpenAI.
The company aims to use this to help to improve the speed and success of drug development and enable customers to get medicines to patients faster and more cost effectively.
The collaboration will deploy OpenAI advanced capabilities within the company’s clinical research business to significantly improve the cycle time of clinical trials, creating meaningful value for the industry.
Thermo Fisher is also shoring up supply chain resilience by continuously expanding its manufacturing footprint through strategic collaborations and acquisitions.
This year, the company completed the acquisition of a state-of-the-art sterile fill-finish and packaging facility in Ridgefield, NJ, from Sanofi.
Thermo Fisher will continue to manufacture a portfolio of therapies for Sanofi at the site, enabling additional S. drug product manufacturing.
The company also expanded by adding the new Filtration and Separation business, following the acquisition of Solventum’s Purification and Filtration business, strengthening it's bioprocessing offerings.
Thermo Fisher has further expanded its sterile-fill finish capabilities with two new filling lines for drug product services in Plainville, Massachussetts, to fulfil critical components in the development and commercialisation of various therapies.
The company also announced a new research and development collaboration with the AstraZeneca BioVentureHub, the open innovation ecosystem in Gothenburg, Sweden, as well as the launch of its innovative Clinical Trial Carbon Calculator.
CPHI attendees are invited to attend the panel discussions at this years show, where Thermo Fisher’s experts will participate in several sessions throughout the conference.
These include the following:
- CDMOs at a Crossroads: Scaling, Adapting and Partnering for the Future, Anil Kane, Global Head of Technical & Scientific affairs, pharma services, Tuesday, Oct. 28, 11:35-12:20 CET, Manufacturing 5.0 Theatre – Hall 4.1-L8
- Make Your Supply Chain Work Smarter: Dual Sourcing With a TCO Twist, Dom Price, Senior Manager of Technical Specialists, CGMP chemical and services-EMEA, bioproduction, Tuesday, Oct. 28, 14:30-14:55 CET, Manufacturing 5.0 Theatre – Hall 4.1-L8
- Environmental Sustainability in Bioprocessing, Paul Ronnander, Director, commercial single use, bioproduction and Carlos Ferrero, Field Application Scientist, process liquids, bioproduction, Tuesday, Oct. 28, 15:00-15:25 CET, Sustainable Futures Theatre – Hall 4.0-G36
- What’s Your Next Move – and What Will It Cost You? Driving Value Under Pressure, Jennifer Cannon, President, commercial operations, pharma services, Wednesday, Oct. 29, 13:30-13:55 CET, Manufacturing 5.0 Theatre – Hall 4.1-L8
- Redrawing the Pharma Investment Map: How Trade and Policy Are Reshaping Capital Flows, Matt Dawes, Vice President, commercial operations, oral drug delivery, pharma services, Thursday, Oct. 30, 11:35-12:15 CET, Manufacturing 5.0 Theatre – Hall 4.1-L8